Lifeward Acquires Exoskeleton Tech, Secures Oramed Partnership for Pipeline Funding
Event summary
- Lifeward received shareholder approval for a strategic investment and technology collaboration agreement with Oramed Pharmaceuticals, acquiring Oramed’s Protein Oral Delivery (POD™) technology platform.
- Lifeward has agreed to acquire a powered upper-body exoskeleton technology with integrated AI capabilities, complementing its ReWalk platform.
- Lifeward achieved expanded reimbursement coverage for its ReWalk Personal Exoskeleton with Aetna, Humana, and UnitedHealthcare, covering approximately 16 million lives.
- Lifeward reported revenue of $5.1 million for Q4 2025, a 33% decrease year-over-year, and $22.0 million for the full year 2025, a 14% decrease year-over-year.
The big picture
Lifeward's strategic shift towards a diversified biomedical innovation company, fueled by the Oramed partnership and exoskeleton acquisition, represents a significant bet on expanding beyond its core neuro-rehabilitation business. This move aims to address the growing demand for advanced medical technologies and secure a more sustainable revenue stream, but carries the risk of diluting focus and complicating operations. The company's ability to effectively manage these new assets and navigate the regulatory landscape will be key to its long-term success.
What we're watching
- Regulatory Headwinds
- The success of the Oramed partnership hinges on the approval and subsequent commercialization of oral biologic therapies, which faces inherent regulatory and clinical trial risks.
- Execution Risk
- Lifeward’s ability to integrate the acquired exoskeleton technology and achieve projected gross margins will be critical to demonstrating the success of its diversified strategy.
- Market Adoption
- The pace at which the expanded reimbursement coverage translates into increased adoption of the ReWalk Personal Exoskeleton will determine the effectiveness of this strategic initiative.
Related topics